A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[11C]methyl)benperidol

Synapse

Volumn 67, Issue 11, 2013, Pages 748-756

  Eisenstein, Sarah A ^a   Antenor Dorsey, Jo Ann V ^a   Gredysa, Danuta M ^a   Koller, Jonathan M ^a   Bihun, Emily C ^a   Ranck, Samantha A ^a   Arbeláez, Ana Maria ^a   Klein, Samuel ^a   Perlmutter, Joel S ^a   Moerlein, Stephen M ^a   Black, Kevin J ^a   Hershey, Tamara ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; NMB; Obesity

Indexed keywords

(N METHYL)BENPERIDOL C 11; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BODY MASS; BODY WEIGHT; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG SELECTIVITY; FEMALE; HUMAN; IMAGING SOFTWARE; INTRAVENOUS CATHETER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; OBESITY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

DOPAMINE; NMB; OBESITY;

ADULT; AGE FACTORS; BENPERIDOL; BODY MASS INDEX; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; OBESITY; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2;

EID: 84884180128     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21680     Document Type: Article

References (51)

1. American Diabetic Association. 2010. Standards of Medical Care in Diabetes-2010. Diabetes Care 33:S11-S61.
2. Antenor-Dorsey JA, Markham J, Moerlein SM, Videen TO, Perlmutter JS. 2008. Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans. Nucl Med Biol 35:335-341.
3. Antonini A, Leenders KL. 1993. Dopamine D2 receptors in normal human brain: Effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Ann NY Acad Sci 695:81-85.
4. Arnett CD, Shiue CY, Wolf AP, Fowler JS, Logan J, Watanabe M. 1985. Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography. J Neurochem 44:835-844.
5. Beaulieu JM, Gainetdinov RR. 2011. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182-217.
6. Beck AT, Steer RA, Brown G. 1993. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
7. Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barth D. 2012. The addictive brain: All roads lead to dopamine. J Psychoactive Drugs 44:134-143.
8. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ. 2012. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: A positron emission tomography study. J Neurosci 32:1353-1359.
9. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ. 1997. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38:1614-1623.
10. Brucke T, Wenger S, Asenbaum S, Fertl E, Pfafflmeyer N, Muller C, Podreka I, Angelberger P. 1993. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol 60:494-500.
11. DeFronzo RA. 2011. Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of Type 2 diabetes. Diabetes Care 34:789-794.
12. de Jong JW, Vanderschuren LJ, Adan RA. 2012. Towards an animal model of food addiction. Obes Facts 5:180-195.
13. de Weijer BA, van de Giessen, van Amelsvoort TA, Boot E, Braak B, Janssen IM, van de Laar A, Fliers E, Serlie MJ, Booij J. 2011. Lower striatal dopamine D2/D3 receptor availability in obese compared with non-obese subjects. EJNMMI Res 1:37.
14. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP. 1993. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
15. Dodds CM, O'Neill B, Beaver J, Makwana A, Bani M, Merlo-Pich E, Fletcher PC, Koch A, Bullmore ET, Nathan PJ. 2012. Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite 59:27-33.
16. Dunn JP, Kessler RM, Feurer IK, Volkow ND, Patterson BW, Ansari MS, Li R, Marks-Shulman P, Abumrad NN. 2012. Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes Care 35:1105-1111.
17. 18F](N-methyl)benperidol using PET. Synapse 66:770-780.
18. Elsinga PH, Hatano K, Ishiwata K. 2006. PET tracers for imaging of the dopaminergic system. Curr Med Chem 13:2139-2153.
19. Faul F, Erdfelder E, Lang AG, Buchner A. 2007. GPower 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175-191.
20. Haltia LT, Rinne JO, Merisaari H, Maguire RP, Savontaus E, Helin S, Nagren K, Kaasinen V. 2007. Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse 61:748-756.
21. Harri M, Mika T, Jussi H, Nevalainen OS, Jarmo H. 2007. Evaluation of partial volume effect correction methods for brain positron emission tomography: Quantification and reproducibility. J Med Phys 32:108-117.
22. Hershey T, Black KJ, Carl JL, McGee-Minnich L, Snyder AZ, Perlmutter JS. 2003. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 4:844-851.
23. Hietala J, West C, Syvalahti E, Nagren K, Lehikoinen P, Sonninen P, Ruotsalainen U. 1994. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl) 116:285-290.
24. Karimi M, Moerlein SM, Videen TO, Luedtke RR, Taylor M, Mach RH, Perlmutter JS. 2011. Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect? Mov Disord 26:100-106.
25. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE. 2005. The World Health Organization Adult ADHD Self-Report Scale (ASRS). Psychol Med 35:245-256.
26. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB. 1995. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
27. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. 1996. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834-840.
28. Moerlein SM, Banks WR, Parkinson D. 1992. Production of fluorine-18 labeled (N-methyl)benperidol for PET investigation of cerebral dopaminergic receptor binding. Appl Radiat Isot 43:913-917.
29. Moerlein SM, Perlmutter JS, Welch MJ. 1995. Specific, reversible binding of [18F]benperidol to baboon D2 receptors: PET evaluation of an improved 18F-labeled ligand. Nucl Med Biol 22:809-815.
30. Moerlein SM, Perlmutter JS, Markham J, Welch MJ. 1997. In vivo kinetics for [18F](N-methyl)benperidol: A novel PET tracer for assessment of dopaminergic D2-like receptor binding. J Cereb Blood Flow Metab 17:833-845.
31. 11C]methyl)benperidol for PET investigation of D2 receptor binding. Radiochem Acta 92:333-339.
32. 11C]methyl)benperidol for clinical application. Eur J Nucl Med Mol Imaging 37:S366.
33. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X, Yasillo N, Chen CT, Mintzer R, Cooper M. 1999. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 26:519-527.
34. 3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int J Neuropsychopharmacol 15:149-161.
35. Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P. 2012. Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 84:882-890.
36. Quarentelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, Alfano B, Brunetti A, Baron JC, Salvatore M. 2004. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 45:192-201.
37. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, Anderson S, Doop M, Woodward N, Schoenberg E, Schmidt D, Baldwin R, Kessler R. 2006. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31:1016-1026.
38. 11C]FLB 457 by use of the GE medical systems PETtrace MeI microlab. J Lab Comp Radiopharm 43:331-338.
39. Shamseddeen H, Getty JZ, Hamdallah IN, Ali MR. 2011. Epidemiology and economic impact of obesity and type 2 diabetes. Surg Clin North Am 91:1163-1172.
40. Steiner JL, Tebes JK, Sledge W, Walker ML. 1995. A comparison of the structured clinical interview for DSM-III-R and clinical diagnoses. J Nerv Ment Dis 183:365-369.
41. Stice E, Yokum S, Blum K, Bohon C. 2010. Weight gain is associated with reduced striatal response to palatable food. J Neurosci 30:13105-13109.
42. Stoeckel LE, Weller RE, Cook EW III, Twieg DB, Knowlton RC, Cox JE. 2008. Widespread reward-system activation in obese women in response to pictures of high-calorie foods. Neuroimage 41:636-647.
43. Suehiro M, Dannals RF Scheffel U, Stathis M, Wilson AA, Ravert HT, Villemagne VL, Sanchez-Roa PM, Wagner HN Jr. 1990. In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol. J Nucl Med 31:2015-2021.
44. Thanos PK, Michaelides M, Ho CW, Wang GJ, Newman AH, Heidbreider CA, Ashby CR Jr, Gardner EL, Volkow ND. 2008. The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav 89:499-507.
45. Videbaek C, Toska K, Scheideler MA, Paulson OB, Moos Knudsen G. 2000. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse 38:338-342.
46. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP. 1993. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169-177.
47. 2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158:2015-2021.
48. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, Alexoff D, Ding YS, Wong C, Ma Y, Pradhan K. 2008. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects. Neuroimage 42:1537-1543.
49. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, Pascani K. 1997. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16:174-182.
50. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS. 2001. Brain dopamine and obesity. Lancet 357:354-357.
51. Wechsler D. 1999. Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio, TX: Harcourt Assessment.